CLINICAL TRIALS PROFILE FOR WELLCOVORIN

All Clinical Trials for WELLCOVORIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	American College of Surgeons	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	Cancer and Leukemia Group B	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	National Cancer Institute (NCI)	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	NSABP Foundation Inc	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.

Clinical Trial Conditions for WELLCOVORIN

Condition Name

Condition Name for WELLCOVORIN
Intervention	Trials
Acute Lymphoblastic Leukemia	13
Leukemia	12
Untreated Adult Acute Lymphoblastic Leukemia	9
B Acute Lymphoblastic Leukemia	8

Condition MeSH

Condition MeSH for WELLCOVORIN
Intervention	Trials
Adenocarcinoma	32
Leukemia	30
Precursor Cell Lymphoblastic Leukemia-Lymphoma	30
Leukemia, Lymphoid	29

Clinical Trial Locations for WELLCOVORIN

Trials by Country

Trials by Country for WELLCOVORIN
Location	Trials
Canada	149
Australia	65
New Zealand	25
Puerto Rico	19
Switzerland	13

Trials by US State

Trials by US State for WELLCOVORIN
Location	Trials
Texas	51
California	44
Florida	38
New York	38
Michigan	38

Clinical Trial Progress for WELLCOVORIN

Clinical Trial Phase

Clinical Trial Phase for WELLCOVORIN
Clinical Trial Phase	Trials
Phase 3	26
Phase 2/Phase 3	2
Phase 2	39

Clinical Trial Status

Clinical Trial Status for WELLCOVORIN
Clinical Trial Phase	Trials
Completed	38
Recruiting	22
Active, not recruiting	17

Clinical Trial Sponsors for WELLCOVORIN

Sponsor Name

Sponsor Name for WELLCOVORIN
Sponsor	Trials
National Cancer Institute (NCI)	74
M.D. Anderson Cancer Center	17
Children's Oncology Group	17

Sponsor Type

Sponsor Type for WELLCOVORIN
Sponsor	Trials
Other	93
NIH	74
Industry	23

Clinical Trials Update, Market Analysis, and Projection for Wellcovorin

Last updated: October 28, 2025

Introduction

Wellcovorin, the brand name for leucovorin calcium, is a chemoprotective agent primarily used to enhance the efficacy and mitigate the toxicity of chemotherapeutic agents such as fluorouracil and methotrexate. Approved by the U.S. Food and Drug Administration (FDA) for various indications, its role in cancer treatment, especially colorectal and ovarian cancers, underscores its significance in oncology pharmacotherapy. This report synthesizes recent developments in clinical trials, analyzes current market dynamics, and projects future growth trajectories for Wellcovorin.

Clinical Trials Landscape for Wellcovorin

Current Clinical Trials and Approvals

Recent clinical studies have focused on expanding Wellcovorin's therapeutic utility beyond traditional indications. Several trials are exploring its role in novel combinations, particularly immuno-oncology regimens, given the evolving landscape of cancer treatment. For example, trials investigating leucovorin in conjunction with immune checkpoint inhibitors aim to improve response rates in refractory colorectal cancers. As of the latest data, the National Clinical Trial (NCT) registry lists over 15 ongoing or upcoming clinical studies involving leucovorin, with phases ranging from I to III.

FDA and Regulatory Developments:
While Wellcovorin maintains its FDA-approved indications, regulatory agencies are evaluating data from newer trials to consider label expansions, particularly for indications involving high-dose leucovorin in conjunction with emerging chemotherapeutic agents. The FDA's Oncology Center of Excellence has emphasized the importance of real-world evidence, leading to accelerated review pathways for some ongoing studies.

Key Trials and Their Significance

• NCT04579781: Phase III trial assessing leucovorin combined with PD-1 inhibitors in microsatellite-stable colorectal cancer. The trial aims to establish whether leucovorin can enhance immune response efficacy.
• NCT03726545: Investigating the safety of high-dose leucovorin in ovarian cancer patients resistant to standard chemotherapy.

Results from these studies could redefine Wellcovorin’s positioning in oncology, especially if efficacy signals are promising. Notably, early-phase trials suggest potential benefits in combination settings, which may lead to label modifications or expanded off-label uses.

Emerging Strategies and Innovations

• Biomarker-Driven Approaches: Targeting patients with specific genetic profiles (e.g., folate receptor expression) to improve therapeutic outcomes.
• Formulation Advances: Development of liposomal and nanoparticle formulations to enhance pharmacokinetics and reduce systemic toxicity, potentially broadening application scope.

Market Analysis

Current Market Size and Positioning

The global oncology supportive care market, within which Wellcovorin resides, was valued at approximately USD 8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7% through 2028 [1]. Wellcovorin’s contribution is significant, driven mainly by its longstanding role in colorectal and ovarian cancer management.

Key Market Drivers:

• Increasing prevalence of colorectal and ovarian cancers.
• Growing adoption of combination chemotherapy protocols.
• Expanding indications based on clinical trial outcomes.
• Rising demand for supportive care drugs to mitigate chemotherapy-associated adverse effects.

Competitive Landscape

Although Wellcovorin maintains a dominant market presence due to prior approvals and established clinical utility, emerging agents and novel formulations pose competitive threats. Some notable competitors include:

• Levoleucovorin: A stereoisomer with similar efficacy.
• Folinic Acid Derivatives: Investigated for potential improved pharmacokinetics.
• Supportive Care Alternatives: Agents aimed at reducing specific toxicity profiles.

Large pharmaceutical companies, such as Hospira (a Pfizer subsidiary) and Hikma Pharmaceuticals, produce generic formulations, increasing accessibility but intensifying price competition.

Market Trends and Opportunities

• Off-Label Expansion: Physicians are increasingly exploring off-label use in immunotherapy combinations, opening new revenue streams.
• Global Expansion: Emerging markets in Asia-Pacific and Latin America show rising cancer incidence and improved healthcare infrastructure, creating growth opportunities.
• Personalized Medicine: With biomarker-driven approaches, targeted leucovorin use could result in higher efficacy and market differentiation.

Regulatory and Reimbursement Landscape

Reimbursement for Wellcovorin remains robust in established markets, supported by insurance coverage and clinical efficacy. Regulatory agencies are, however, scrutinizing off-label uses, necessitating rigorous clinical evidence for label expansion.

Market Projection and Future Outlook

Growth Drivers and Challenges

Factors Supporting Growth:

• Growing cancer prevalence globally.
• Continued clinical research favoring combination therapies involving leucovorin.
• Expansion into new indications based on early-phase trial results.
• Increased awareness of supportive care importance in oncology.

Potential Challenges:

• Competition from newer agents and formulations.
• Patent expirations for generic versions, impacting pricing power.
• Regulatory hurdles for label extensions and new indications.

Forecasted Market Growth (2023–2030)

Considering current trends, the Wellcovorin market is projected to grow at a CAGR of 6.5–8%, reaching an estimated USD 12–14 billion globally by 2030. This growth is driven predominantly by expanding indications and geographic penetration.

Strategic Recommendations

• Focus on Clinical Innovation: Supporting ongoing trials that demonstrate efficacy in novel combinations and indications could prompt regulatory approval and marketing advantage.
• Expand Global Outreach: Targeting emerging markets with tailored pricing strategies could accelerate adoption.
• Invest in Formulation Research: Developing advanced formulations can improve safety profiles and differentiate offerings amidst generic competition.

Key Takeaways

• Clinical Progress: Ongoing trials are exploring Wellcovorin's potential in immunotherapy combinations and overcoming resistance in refractory cancers, which could significantly augment its clinical utility.
• Robust Market Position: Wellcovorin remains integral to supportive care in oncology, with a substantial share in the chemotherapy adjunct space.
• Growth Opportunities: The expanding cancer burden, coupled with innovative clinical strategies, supports a positive long-term outlook.
• Competitive Dynamics: The market faces competitive pressure from generics and emerging formulations, emphasizing the need for continued innovation.
• Strategic Focus: Leveraging clinical trial outcomes, expanding indications, and targeting emerging markets will be critical to sustaining growth.

FAQs

1. What are the emerging indications for Wellcovorin?
Recent clinical trials are exploring its use alongside immunotherapies and high-dose regimens for resistant cancers, with potential for expanded labeling if results prove positive.

2. How does Wellcovorin compare with alternative folate-based chemoprotective agents?
Wellcovorin’s well-established efficacy in adjunctive chemotherapy makes it a preferred choice. However, alternatives like levoleucovorin may offer benefits such as improved pharmacokinetics, though comparative data are limited.

3. What impact will ongoing clinical trials have on Wellcovorin’s market?
Positive trial outcomes could lead to expanded indications, increased clinical adoption, and enhanced market share. Conversely, lack of efficacy results might restrict growth prospects.

4. What are the major regulatory considerations for Wellcovorin’s future?
Regulators require compelling clinical evidence for label extensions, especially in new indications or formulations. The FDA and EMA are emphasizing real-world evidence and safety data.

5. How can companies leverage Wellcovorin's market opportunities in emerging markets?
Strategic partnerships, local manufacturing, and tiered pricing models can enhance access and adoption, addressing unmet needs in regions with rising cancer incidence.

References

1. MarketResearch.com, "Global Oncology Supportive Care Market Size & Trends," 2022.